Giant Biogene Holding Co., Ltd.
Giant Biogene Holding Co., Ltd. Fundamental Analysis
Giant Biogene Holding Co., Ltd. (2367.HK) shows strong financial fundamentals with a PE ratio of 14.00, profit margin of 34.73%, and ROE of 19.93%. The company generates $5.4B in annual revenue with strong year-over-year growth of 57.17%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 87.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 2367.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent2367.HK demonstrates superior asset utilization.
Valuation Score
Excellent2367.HK trades at attractive valuation levels.
Growth Score
Excellent2367.HK delivers strong and consistent growth momentum.
Financial Health Score
Excellent2367.HK maintains a strong and stable balance sheet.
Profitability Score
Excellent2367.HK achieves industry-leading margins.
Key Financial Metrics
Is 2367.HK Expensive or Cheap?
P/E Ratio
2367.HK trades at 14.00 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 2367.HK's PEG of -0.82 indicates potential undervaluation.
Price to Book
The market values Giant Biogene Holding Co., Ltd. at 2.69 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 14.83 times EBITDA. This signals the market has high growth expectations.
How Well Does 2367.HK Make Money?
Net Profit Margin
For every $100 in sales, Giant Biogene Holding Co., Ltd. keeps $34.73 as profit after all expenses.
Operating Margin
Core operations generate 38.46 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $19.93 in profit for every $100 of shareholder equity.
ROA
Giant Biogene Holding Co., Ltd. generates $17.54 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Giant Biogene Holding Co., Ltd. generates strong operating cash flow of $1.80B, reflecting robust business health.
Free Cash Flow
Giant Biogene Holding Co., Ltd. generates strong free cash flow of $1.44B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.38 in free cash annually.
FCF Yield
2367.HK converts 5.65% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
14.002
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.82
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.69
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.77
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
11.27
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.20
vs 25 benchmark
ROA
Return on assets percentage
0.18
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How 2367.HK Stacks Against Its Sector Peers
| Metric | 2367.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 14.00 | 22.36 | Better (Cheaper) |
| ROE | 19.93% | 1238.00% | Weak |
| Net Margin | 34.73% | -5096.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 1.23 | Strong (Low Leverage) |
| Current Ratio | 11.27 | 2.47 | Strong Liquidity |
| ROA | 17.54% | -191998.00% (disorted) | Strong |
2367.HK outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Giant Biogene Holding Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
473.44%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthEPS CAGR
269.88%
Industry Style: Defensive, Dividend, Low Volatility
High GrowthFCF CAGR
207.98%
Industry Style: Defensive, Dividend, Low Volatility
High Growth